29. Jul 2026
Description
(AWP Alliance News) - Basilea Pharmaceutica AG highlighted continued momentum in its hospital anti-infectives franchise, led by Cresemba, which generated USD 782 million in in-market sales over the 12 months ended March 2026, up 27% year over year. The group reiterated its asset-light partnering model, with Cresemba marketed in 76 countries and Zevtera launched in the US in July 2025 through Innoviva Specialty Therapeutics.
Basilea pointed to US market exclusivity for Zevtera until April 2034, citing early formulary wins and reimbursement progress. It also set out late-stage development priorities, with phase 3 programs under way for fosmanogepix in invasive candidiasis and invasive mold infections.
Separately, it expects to initiate a global phase 3 program for oral ceftibuten-ledaborbactam in complicated urinary tract infections in early 2027.
https://docs.publicnow.com/0260E2E83294257F491B6B025782493A1C36E209
Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.
